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How long does a hip replacement last? A systematic review 
and meta-analysis of case series and national registry reports 
with more than 15 years of follow-up
Jonathan T Evans, Jonathan P Evans, Robert W Walker, Ashley W Blom, Michael R Whitehouse*, Adrian Sayers*
Summary
Background Total hip replacement is a common and highly effective operation. All hip replacements would eventually 
fail if in situ long enough and it is important that patients understand when this might happen. We aimed to answer 
the question: how long does a hip replacement last?
Methods We did a systematic review and meta-analysis with a search of MEDLINE and Embase from the start of 
records to Sept 12, 2017. We included articles reporting 15-year survival of primary, conventional total hip replacement 
constructs in patients with osteoarthritis. We extracted survival and implant data and used all-cause construct survival 
as the primary outcome. We also reviewed reports of national joint replacement registries, and extracted data for a 
separate analysis. In the meta-analyses, we weighted each series and calculated a pooled survival estimate for each 
source of data. This study was registered with PROSPERO (CRD42018085642).
Findings We identified 140 eligible articles reporting 150 series, and included 44 of these series (13 212 total hip 
placements). National joint replacement registries from Australia and Finland provided data for 92 series (215 676 total 
hip replacements). The 25-year pooled survival of hip replacements from case series was 77·6% (95% CI 76·0–79·2) 
and from joint replacement registries was 57·9% (95% CI 57·1–58·7).
Interpretation Assuming that estimates from national registries are less likely to be biased, patients and surgeons can 
expect a hip replacement to last 25 years in around 58% of patients.
Funding National Institute for Health Research, National Joint Registry for England, Wales, Northern Ireland and Isle 
of Man, and The Royal College of Surgeons of England.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Total hip replacement is one of the most common and 
effective forms of surgery, resulting in generally ex­
cellent outcomes.1 In an immortal cohort, all hip re­
placements will eventually fail because of processes 
such as infection, fracture, or a combination of normal 
tribological and biological processes, such as loosening 
and wear.
To counsel patients accurately and appropriately, 
benchmark treatment strategies, plan health­care 
provision, and for medicolegal purposes, it is important 
to know how long a total hip replacement might last. 
Life expectancy is rising and thus the long­term 
survivorship of the total hip replacement construct is 
increasingly relevant. The ultimate aim, that all hip 
replacements provide normal pain­free function for the 
rest of the recipients lives, has not been achieved. In the 
UK, the National Institute of Health and Care Excell­
ence set a benchmark in 2014, that individual com­
ponents making up a total hip replacement are only 
recommended for people with end­stage arthritis, if 
they have 10­year revision rates of 5% or lower.2 
The Orthopaedic Data Evaluation Panel assists in the 
implementation of this guidance, producing sum­
mary 10­year revision rates for individual prostheses 
using multiple data sources. At present, it does not 
publish revision rates for hip replacements, but only 
constituent parts.
Patients who undergo hip replacement surgery are at 
risk of revision surgery. The commonest reasons for 
revision are infection, wear, loosening, dislocation, 
persistent pain, and fracture. Revision surgery is not as 
effective as primary surgery for relieving pain and 
improving function and is more expensive.3,4 Further­
more, revision hip replacements fail much earlier than do 
primaries, necessitating further revisions.5
The typical patient who had a hip replacement in the UK 
in 2016 was 69·8 years old if female or 67·6 years old if 
male, and had a BMI of 28·8. 90% of hip replace­
ments were done for osteoarthritis and 60% of recipients 
were female.6 Similar demographics are reported by 
the national registries in Scandinavia, Australia, and 
the Netherlands.7–9
We wished to answer a question that is posed to us by 
our patients many times per day: how long does a hip 
replacement last?
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Methods
Study design and data sources
We did a systematic review and meta­analysis of case 
series and cohort studies reporting survival outcomes of 
total hip replacements. We did a second meta­analysis of 
national joint replacement registries with more than 
15 years of follow­up.
To collect data for the analysis of case series, we 
systematically searched for case series and cohort studies 
in English reporting survival outcomes of total hip 
replacements in MEDLINE and Embase from com­
mencement to Sept 12, 2017. The search of MEDLINE 
used keywords relating to total hip replacement, survival, 
and MeSH terms (appendix p 1). The search strategy for 
Embase was the same. We manually screened the 
bibliographies of all full­text articles matching our 
criteria, as well as review articles, for additional citations.
We included studies if they involved predominantly 
unselected patients or patients undergoing total hip 
replacement for osteoarthritis. We required the reporting 
of survival of a specific implant, brand, or construct with 
a mean or median follow­up of greater than 15 years. We 
excluded articles reviewing specifically complex primary 
total hip replacement, revision, or hip resurfacing, be­
cause these procedures have different survivorship. We 
also excluded conference abstracts because they were 
unlikely to contain enough information. Some articles 
reported implant construct survivorship from registry 
data, we excluded these studies to avoid duplication with 
our separate analysis of joint registries. We retrieved 
systematic reviews and searched their bibliographies 
but we did not include pooled data from the reviews 
themselves to avoid duplication.
For the analysis of data from national joint replacement 
registries, we assessed the six registries that had greater 
than 15 years of follow­up for total hip replacement at the 
time of data collection in December, 2017: Australia, 
Denmark, Finland, New Zealand, Norway, and Sweden. 
We reviewed the websites and most recent annual reports 
of these registries for data on conventional, stemmed, 
total hip replacement constructs. These national regis­
tries collect data on all patients undergoing total hip 
replacement from both public and private hospitals 
and their aim is to include all total hip replacements in 
their cohort.
Abstract screening and data extraction
We screened the abstracts of journal articles using 
Rayyan,10 by three reviewers (JTE, RWW, JPE) and in cases 
of disagreement, were included for review. Either JTE or 
JPE and RWW together extracted data using a standardised 
proforma. We recorded, when available, data for pub­
lication date, implant, fixation, number of total hip 
replacements, age, sex, indication, loss to follow­up, and 
summary survivorship estimates (including confidence 
intervals) at all timepoints reported, as well as data for 
quality assessment. We did not abstract data from figures 
to prevent potential inaccuracy. Any discrepancy of data 
extraction was rectified by review of the full text by all three 
reviewers. There were no cases of disagreement after this.
Statistical analysis
Our primary exposure was the total hip replacement 
construct and all­cause revision of any part of the 
construct was our endpoint. We did the statistical analysis 
with Stata (version 15). We pooled survival estimates, 
assuming that survivorship approximated risk, with 
meta­analysis weighting each series on the overall pooled 
estimate according to its standard error (calculated from 
published confidence intervals).
We assessed study quality using the non­summative 
four­point system (consecutive cases, multicentre, less 
than 20% loss to follow­up, and use of multivariable 
analysis) developed by Wylde and colleagues.11 We used 
this system rather than the summative MINORS score12 
because of the high loss to follow­up in joint replacement 
Research in context
Evidence before this study
Survival of hip replacements has often been reported in case 
series, some of which extend to 40 years. We identified 
140 articles reporting case series through a search of MEDLINE 
and Embase (from start of records to Sept 12, 2017) analysing 
single hip replacement constructs, implanted for osteoarthritis. 
These articles report estimates of survival at 15 years ranging 
from 48·0% to 93·2%. However, individual case series are prone 
to bias and reporting has been highly heterogeneous. Joint 
replacement registries provide more generalisable data but have 
only existed since 1975 and have limits in terms of the variables 
collected and interpretation. Survival of a hip replacement is 
dependent on the implants used to create a construct and on 
patient characteristics. A pooled estimate of 20-year survival of 
85·0% (95% CI 83·2–86·6) using the UK Clinical Practice 
Research Datalink database was published in 2017. No study to 
date has attempted to provide a pooled survival calculation for 
hip replacements 25 years after surgery.
Added value of this study
Our results provide the first survival estimate, drawn from 
multiple sources, for hip replacements at 25 years. This study 
benefits from an inclusive design, a-priori inclusion criteria, 
and a realistic interpretation of survivorship. We estimate that 
roughly 58% of hip replacements will last 25 years.
Implications of all the available evidence
Estimates of the survival of hip replacements will be of use to 
patients, those providing and commissioning health-care 
services, and those needing an estimate for medicolegal 
purposes.
See Online for appendix
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case series and because some of the scoring criteria were 
not relevant to joint replacement.
This study was registered with PROSPERO 
(CRD42018085642).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Our search produced 4195 references. We removed 
1445 duplicates, leaving 2750 reports for screening. After 
screening, 299 full texts were left for review with 
20 additional citations identified by a manual search of 
references and reviews (appendix p 2). We excluded 
13 articles not in English.13–25 Following a review of full 
texts, 140 journal articles reporting 150 case series reported 
survivorship of implants; in total, these articles report on 
58 932 total hip replacements (range 38–22 036). 78 of 
150 case series reported all­cause construct survival and 
44 of these included confidence intervals (required for 
meta­analysis; figure 1). The table shows the char­
acteristics of individual studies (appendix p 3 shows the 
full list of included articles and survival estimates).
The 44 case series included reported all­cause construct 
survival in 13 212 total hip replacements (range 73–2000), 
with follow­up ranging from 15 to 40 years. Not all series 
reported survival at exactly 15, 20, or 25 years and some 
series reported survival at more than one time. Pooled 
analysis of data derived from case series of total hip 
replacements reported at exactly 15 years, 20 years, and 
25 years showed all­cause survivorship of the cons­
truct of 85·7% (95% CI 85·0–86·5) at 15 years, 78·8% 
(77·8–79·9) at 20 years, and 77·6% (76·0–79·2) at 
25 years (figure 2).
In analysis in which survival at timepoints that were 
not exactly 15, 20, or 25 years were rounded down to the 
closest point (to include as many series as possible in 
our analyses), which gave pooled survival of 87·9% 
(87·2–88·5) at 15 years, 78·9% (77·9–80·0) at 20 years, 
and 76·6% (75·1–78·2) at 25 years (appendix p 8).
Generally, the quality of published case series was low. 
The quality assessment showed that 24 (54·5%) of 44 series 
were consecutive, none were multicentre, five (11·4%) 
had less than 20% follow­up, and seven (15·9%) used 
multivariable analyses.
The search of joint replacement registry reports yielded 
92 series, and all provided confidence intervals. All 
92 individual construct series reported survival analyses 
at 15 years (215 676 total hip replacements), 43 series at 
20 years (73 057 total hip replacements), and 29 series at 
25 years (51 359 total hip replacements). The pooled 
survival data derived from registry data showed all­cause 
construct survivorship of 89·4% (95% CI 89·2–89·6) at 
15 years (appendix p 9), 70·2% (69·7–70·7) at 20 years 
(appendix p 10), and 57·9% (57·1–58·7) at 25 years 
(figure 3). The 15 year data included series originating 
from the Australian and Finnish registries, whereas the 
2750 search results screened
299 full text articles reviewed
140 articles included 
(150 individual series)
2451 excluded after screening
897 had insufficient follow-up
882 not primary hip replacement
435 no survival analysis
320 specific to a disease other than osteoarthritis
5 other
179 excluded
123 insufficient follow-up or no survival analysis
22 systematic reviews
20 based on registry data
13 not English
1 more than one construct20 additional articles identified from 
manual search of references
34 series did not provide 
confidence intervals
78 series reporting all-cause construct survival 72 series did not report all-cause construct 
survival
44 eligible series
Figure 1: Article selection
Individual 
case-series articles
Australian Orthopaedic 
Association National Joint 
Replacement Registry 
Annual report 2017
Finnish 
Arthroplasty 
Report November 
2017
Study level characteristics
Location 16 countries Australia Finland
Number of series included 44 36 56
Year of publication 1993–2017 2017 2017
Participant level characteristics
Total joint replacements included 13 212 121 384 94 292
Mean age (years) 57·9* 67·7† 65–74‡
Proportion of female patients 56·2%§ 55%† 58·5%†
Proportion of hips implanted for 
osteoarthritis
61·8%§ 88·5%† Not reported
*Weighted mean for age by number in study. †All conventional total hip replacements in report. ‡Exact figure not 
reported; the median is within this range. §Weighted proportion by number in study.
Table: Characteristics of contributing data sources
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20 year and 25 year data were exclusively from the 
Finnish registry. The other four arthroplasty registries 
with 15 years potential follow­up did not provide survival 
estimates broken down by the stem–cup combination 
and therefore could not be used in our analyses. 
Figure 4 shows a comparison of the point estimates at 
each timepoint for the data two sources.
Discussion
Patients often ask clinicians how long their hip replacement 
will last. Until now, we have not had a generalisable answer 
to this question. We found that, according to registry data, 
just over half of hip replacements last 25 years. Published 
case series suggest better survivorship at 20 years and 
25 years. The data from the two sources are similar at 
15 years.
Concordance at 15 years is encouraging, but the dif­
ferences at 20 and 25 years suggest that the two types of 
data probably have different sources of bias. Case series 
are particularly prone to selection bias, which is not 
a feature of registries and might lead to the study 
population not being representative of the target popu­
lation. Case series are also more prone to publication 
bias, with clinicians and editors more likely to publicise 
results if good. Ideally, national registries capture the 
entire population, but in reality, they are limited by the 
quality of data submitted to the registry. Case series are 
usually selected and thus not necessarily generalisable, 
but if rigorously done can have better data complete ness 
and contain a wider set of variables. The smaller 
numbers of patients in case series compared with 
registries means that loss to follow­up should be easier 
to prevent, whereas registry data are reliant on the 
correct linkage of a primary operation to the revision 
procedure. This might result in a form of selection bias 
in the registry data. In our review of case­series however, 
there was considerable variation in the number of 
patients lost to follow­up, suggesting that this is also 
a potential source of bias in case series. We think 
therefore that the difference in the survival estimates 
between the sources is in part down to the different 
biases in the two types of study. Regardless of potential 
sources of bias, the more conservative and generalisable 
estimates provided by the registry annual reports are 
likely to be more reliable.
The age and sex distribution of our studies are the 
same as those reported by the largest national registries 
such as the National Joint Registry for England, Wales, 
Northern Ireland and the Isle of Man (NJR), and the 
Swedish Hip Arthroplasty Register suggesting that our 
data are likely to be generalisable.6,7 Survivorship of 
arthroplasties correlates strongly with age, sex, and im­
plant selection and this must be considered when 
counselling patients.
Although our findings might be generalisable, they 
are also by definition historic, as there are secular 
changes in health service delivery, implant design, and 
patient characteristics. Several of the components that 
make up the hip replacement constructs in our analyses 
are no longer widely used. There were no articles 
reporting individual case series that assessed a construct 
used more than 250 times in the NJR 2016 annual 
report. In the 92 registry annual report series only four 
constructs (reported in five series) were still in common 
use and only 15­year survival data were available. 
400 6020 80 100
Survival (95% CI) Weight (%)Date
15 years
Nercessian et al
Neumann et al
Berry et al
Gerritsma-Bleeker et al
Wroblewski et al
Corten et al
Trebse et al
Toni et al
Madey et al
Corten et al
Mullins et al
Boyer et al
Subtotal
20 years
Wroblewski et al
Corten et al
Neumann et al
Hartofilakidis et al
Boyer et al
Klapach et al
Anseth et al
Hartofilakidis et al
Belmont et al
Hartofilakidis et al
Devitt et al
Nercessian et al
Cruz-Pardos et al
Corten et al
Hartofilakidis et al
Mullins et al
Kolb et al
Berry et al
Schulte et al
Sochart et al
Subtotal
25 years
Skutek et al
Sochart et al
Buckwalter et al
Berry et al
Sochart et al
Wroblewski et al
Georgiades et al
Mullins et al
Subtotal
2005
1994
2002
2000
2002
2011
2005
2017
1997
2011
2007
2011
2002
2011
1994
2015
2011
2001
2010
1997
2008
1997
1997
2005
2017
2011
1997
2007
2012
2002
1993
1997
2007
1997
2006
2002
1998
2002
2009
2007
84·20 (81·40–87·00)
91·80 (88·00–95·60)
89·80 (88·30–91·20)
91·00 (86·00–97·00)
84·70 (82·40–87·10)
66·00 (61·40–70·60)
48·00 (44·00–52·00)
93·20 (89·00–97·30)
86·00 (82·00–90·00)
79·50 (75·70–83·30)
89·50 (87·80–91·20)
81·40 (76·20–86·60)
85·74 (84·95–86·54)
74·20 (70·50–78·00)
69·40 (64·30–74·50)
89·30 (84·60–94·00)
73·00 (67·20–78·80)
75·40 (69·20–81·50)
82·00 (78·00–86·00)
84·70 (74·70–91·50)
67·00 (58·00–76·00)
74·30 (67·60–81·00)
60·00 (51·70–68·30)
75·00 (66·00–84·00)
66·20 (60·50–71·90)
84·10 (73·91–94·29)
47·90 (41·30–54·50)
80·00 (71·70–88·30)
84·10 (81·30–86·90)
65·00 (55·00–73·00)
84·10 (82·20–85·90)
80·00 (72·00–88·00)
67·00 (61·00–74·00)
78·81 (77·75–79·86)
83·00 (77·00–89·00)
65·00 (58·00–72·00)
80·00 (73·00–87·00)
80·90 (78·40–83·00)
65·00 (54·00–76·00)
65·60 (58·40–72·80)
51·00 (39·00–62·00)
77·40 (74·20–80·60)
77·62 (76·02–79·22)
8·13
4·41
30·31
2·11
11·54
3·01
3·98
3·70
3·98
4·41
22·05
2·36
100·00
7·92
4·28
5·04
3·31
2·94
6·96
1·58
1·37
2·48
1·62
1·37
3·43
1·07
2·56
1·62
14·20
1·37
32·52
1·74
2·63
100·00
7·12
5·23
5·23
48·42
2·12
4·94
1·94
25·01
100·00
Survival (95% CI)
Figure 2: Estimates of survival at 15 years, 20 years, and 25 years from case series
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Compared with our pooled results, these constructs had 
high 15­year survival (94·9%, 95% CI 93·9–94·8; 
appendix p 11). The constructs were the Exeter 
V40/Trident, Exeter V40/Exeter Contemporary Flanged, 
CPT/Trilogy, and CPT/ZCA. The 22 589 total hip replace­
ments that used one of these combinations accounted 
for a quarter of total hip replacement constructs 
implanted in England and Wales in 2016.6 Using 
constructs with better survival should mean that 
revision rates will reduce in the future: overall revision 
rate by year of surgery has already decreased since 
2008.6
Estimates of the lifetime risk of revision for hip re­
placements have been calculated using primary care 
databases (the UK Clinical Practice Research Datalink).
Bayliss and colleagues reported a 20 year survival 
of 85·0% (95% CI 83·2–86·6) from analysis of 
63 158 patients with a maximum follow­up of 20 years. 
This survival estimate is higher than our 20 year 
estimates. The mean age of patients in their cohort was 
69 years and 62% were female, similar to our data. The 
difference in estimates could be due to several factors: 
the authors used a different database, covering a 
different time period (1991–2011 rather than 1980–2017 
for the Finnish registry). Also, they used a life­table 
analysis method rather than the Kaplan­Meier estimator 
used in most studies included in our analysis. Most 
notable was the numbers of patients with hip 
replacements at each reporting time. Bayliss and 
colleagues reported 20 year survival data on 444 patients 
compared with the 73 057 hip replacements 20­year 
survival data in our study. The focus of Bayliss and 
colleagues’ paper was the lifetime risk of revision of a 
joint replacement, which is not what we have reported. 
They surmised that the lifetime risk of revision changed 
according to the age of the patient at the time the hip 
replacement was implanted, with older patients having 
a lower lifetime risk of revision. Our lower survival at 
20 years is likely to support their conclusion that if a 
patient has a hip replacement at a younger age, then the 
chances of the patient having revision surgery are 
higher. Several overall survival estimates have also been 
produced using data from Nordic arthroplasty registries. 
These studies mostly focus on specific cohorts, such as 
Registry Survival (95% CI) Weight (%)
Biomet head-neck/PFU
Biomet dysplastic stem/PFU
Biomet interlock/Biomet all poly
Müller SLS titanium/Müller standard
Bimetric collarless/Harris-Gallante porous II
Brunswick/Brunswick
Bimetric collarless/Romanus
Christiansen/Christiansen
McKee Arden/McKee Arden
Müller monoblock/RM with HA
Link RS/Link lubinus K cup
Bimetric collared/PFU
Lubinus SPI/Link IP
Biomet interlock/Biomet Müller-Type
Bimetric collarless/TTAP
PCA Standard/PCA pegged
ABG I/ABG I
Bimetric collarless/Mallory
Anatomic mesh/Harris-Gallante porous II
Exeter/Exeter metalback
Mathys isoelastic/RM
Lord madreporique/Lord
Charnley/Charnley LPW
Müller monoblock/Müller standard
Lubinus SP II/Lubinus eccentric
Bimetric collarless/PFU
Exeter universal/Exeter all poly
Lubinus IP/Link IP
Lubinus SPII/Link IP
Overall
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
Finnish
53·40 (45·10–63·20)
61·00 (54·80–67·90)
60·50 (41·50–88·30)
74·70 (68·70–81·30)
47·20 (39·30–56·80)
59·30 (52·70–66·80)
40·20 (35·40–45·70)
35·00 (28·70–42·60)
62·40 (55·00–70·90)
76·00 (69·50–83·10)
40·20 (35·60–45·30)
54·10 (49·00–59·70)
35·50 (29·90–42·20)
38·50 (9·60–100·00)
10·50 (7·90–14·00)
48·40 (44·20–53·00)
51·60 (47·10–77·00)
63·70 (58·10–69·90)
57·00 (53·20–61·00)
60·70 (56·50–65·20)
57·20 (53·60–60·90)
41·60 (39·00–44·50)
57·40 (54·00–61·10)
76·80 (73·80–79·90)
63·20 (35·90–100·00)
61·20 (59·10–66·00)
73·90 (69·40–78·60)
65·50 (63·70–67·40)
79·10 (76·90–81·40)
57·92 (57·14–58·71)
0·75
1·44
0·11
1·55
0·80
1·24
2·32
1·28
0·97
1·33
2·62
2·15
1·63
0·03
6·62
3·18
0·28
1·77
4·05
3·26
4·62
8·15
4·89
6·62
0·06
5·18
2·91
18·00
12·17
100·00
  
60
Survival (95% CI)
80 1000 20 40
Figure 3: Estimates of survival at 25 years from registry annual reports
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patients older than 55 years, younger than 55 years, or 
with a particular class of hip replacement (cemented or 
cementless), but two studies produced generalised 
estimates for all hip replacements. A 2014 collaborative 
report28 from the combined Nordic Arthroplasty Registry 
Association reg istry gave 15 year survival estimates of 
86% (95% CI 85·7–86·9) in Denmark, 88% (87·6–88·3) 
in Sweden, 87% (86·4–87·4) in Norway, and 84% 
(82·9–84·1) in Finland. Fevang and colleagues’ 2010 
article29 reported a 20 year survival estimate of 77·3% 
(76·3–78·4) from the Norwegian registry with 280 hips 
at risk at this timepoint.
We found heterogeneity in the reporting of case 
series, particularly in the handling of patients lost to 
follow­up, the point at which survival was reported, and 
the number of hips at risk at the analysis point. We 
think that the primary endpoint of any analysis 
reporting joint replace ment survivorship should be all­
cause revision of any component of the construct. 
Although other endpoints, for example, failure of a 
single part of the construct or failure for a specific 
cause (such as aseptic loosening), were reported in 
series included in our review30,31 and might be of 
interest, they should only be reported as secondary 
endpoints because they give a biased and unrealistic 
impression of survivorship.32 We have ex plained 
elsewhere,33 why the 1–Kaplan­Meier estimate is the 
most appropriate method of reporting survivorship 
(with a worst­case scenario for hips lost to follow­up) 
and should include the number of hip replacements at 
risk at the time of reporting. 
Failure in arthroplasty can be measured many ways 
and patients who report failure in one metric often 
report success using another metric. Furthermore, 
revision surgery is a major intervention with uncertain 
outcome and thus both clinicians and patients might 
decide that the risks outweigh the benefits in individual 
cases. Failure measured by revision should thus be 
considered a best­case scenario. As the aim of surgery is 
to relieve pain, then a very stringent criterion could 
define failure as all patients with moderate­to­severe 
long­term pain. Beswick and colleagues34 have shown 
that 7–23% of patients who have not undergone revision 
would be regarded as failures using this outcome.
The main limitation of our pooled data is that they 
were not adjusted or stratified by patient factors that 
could have a role in determining survivorship. NJR data 
show that at 10 years, construct survivorship in men is 
roughly 97% for those aged older than 80 years, 96% for 
those aged 60–70 years, and 95% for those aged younger 
than 60 years. Women have slightly better construct 
survivorship at all ages than men. Without individual 
patient data, we have been unable to provide a risk 
estimate adjusted for individual characteristics such as 
age and sex, so our analyses provide an aggregated 
estimate for survival in all patients. Information was 
unavailable for the proportion of hips implanted for 
osteoarthritis in the Finnish Arthroplasty Registry. If 
this proportion was different to that seen in other 
countries, then it could be a source of selection bias. 
Poor implant choices such as metal­on­metal bearings 
will result in much higher failure rates.35,36 Use of metal­
on­metal bearing surfaces in the NJR peaked in 2008, 
with only 404 reported in the NJR in 2003.36 The hips 
included in our estimates were implanted before 2003, 
and thus should be unaffected by the higher failure rates 
of metal­on­metal hip replacements. Since 2003, the 
thresholds for undertaking surgery may have changed, 
which could alter future outcomes. As with all survival 
reports, we cannot account for a surgeon’s willingness to 
revise a hip based on individual patient factors. This 
revision threshold could differ between countries and 
affect the generalisability of results between nations. 
Our pooled results from registries include data from 
only a few countries; however, the number of hip 
replacements was still far greater than that seen in 
individual case­series (215 676 vs 13 212).
Data contributing to 15­year survival came from both 
Australian and Finnish registries; however, results at 
20 years and 25 years came only from the Finnish 
registry. We excluded papers not in English, which 
potentially excluded 13 further series. If all these case 
series were included they might have altered our pooled 
results, but we expect this effect would have been small. 
We assumed that survival estimates are equivalent to 
215 676 hips at start (92 series)
7192 hips at start (20 series) 4617 hips at start (8 series)
5792 hips at start (12 series)
73 057 hips at start (43 series)
51 359 hips at start (29 series)
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Figure 4: Comparison of pooled survival estimates from case series and registry reports at 15 years, 20 years, 
and 25 years
The size of each circle is proportional to the total number of hip replacements at the start of all the series 
contributing to that pooled estimate.
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risks, for gener ating pooled estimates, and although 
the assumption that no censoring occurs (patients 
dying with a hip in situ) is clearly violated, it provides a 
useful method of aggregation in the absence of 
individual patient level data. The strengths of our study 
include an inclusive and com prehensive design, 
a­priori inclusion criteria, and a realistic interpretation 
of survivorship that accounts for all revisions and not a 
limited or biased subset.
In conclusion, although there is not enough infor­
mation yet available to calculate exactly how long a hip 
replacement will last, using available arthroplasty 
registry data, we estimate that about three­quarters of 
hip re placements last 15–20 years and just over half 
of hip replacements last 25 years in patients with 
osteoarthritis (video).
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